-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Recently, many pharmaceutical companies have announced the failure of new drug development
.
For example, Merck announced recently that it has discontinued the Phase 3 clinical trial of its PD-1 product Keridax and the PARP inhibitor lipdrox in the treatment of metastatic castration-resistant prostate cancer because, after an interim data analysis, it was found that , compared with the control group abiraterone acetate or enzalutamide, Kreida combined with lipdroid did not show a survival benefit
.
Pharmaceutical companies have embarked on the road of innovation (Source: Pharmaceutical Network) In addition, on March 14, Sanofi also announced amcenestrant as a second-line or multi-line monotherapy for the treatment of ER+/HER2- advanced or metastatic breast cancer.
There was no news that the trial met its primary endpoint
.
According to an independent central review assessment, amcenestrant did not improve progression-free survival compared with a physician's choice of single-agent endocrine therapy
.
In addition to the above companies, many pharmaceutical companies have encountered setbacks in drug research and development this year, including Beijing Kangchen's withdrawal of the clinical trial application for teriparatide injection, and the failure of Kodiak's ultra-long-acting anti-VEGF therapy Phase IIb/III clinical trials.
.
.
According to the industry, the investment of large pharmaceutical companies in drug innovation has been increasing in recent years, but there are still very few new drugs that can enter the market every year, and the number of failed new drug R&D projects is still increasing day by day
.
Innovative drugs represent a country's technical level and capabilities in the field of medicine, and judging from the repeated "premature deaths" of innovative drug research and development, pharmaceutical companies still have a long way to go in new drug research and development
.
It is understood that the research and development of new drugs has always been difficult and the technical threshold is high.
The success rate from compound screening to listing is only 3‰.
The research and development of each innovative drug takes at least 10 years, and the initial investment cost is high
.
Taking the United States, which has a high level of innovative drug research and development as an example, the average cumulative investment of a single innovative drug is 600 million to 1 billion US dollars, while the average innovative drug research and development in China is as high as several hundred million yuan.
.
In this context, for domestic and foreign pharmaceutical companies, it is still not easy to develop a new drug
.
In the future, how to establish a project to develop new drugs with real clinical and market value, stand out from the homogeneous R&D, and accelerate the listing in China and even overseas will still be a long-term challenge faced by domestic pharmaceutical companies and new drug development institutions and will take time to research.
subject
.
In addition, it should be noted that under the background that innovation and research and development have become the general trend of pharmaceutical companies, as instruments and machines that directly contact drugs, the upgrading of pharmaceutical equipment cannot be ignored.
Whether it is quality upgrade or innovation upgrade, high-quality, High-tech and intelligent pharmaceutical equipment and instruments will bring more benefits to pharmaceutical companies
.
Especially in the current situation of accelerating innovation and reform of the domestic and foreign pharmaceutical industries, pharmaceutical equipment companies need to accelerate innovation and upgrading in order to help the pharmaceutical industry and pharmaceutical companies to further develop with high quality
.
It is reported that in fact, there are many pharmaceutical equipment companies, which are developing in the direction of multi-function, low energy consumption, intelligence and more suitable for pharmaceutical industrial production under the background of making full use of Internet, Internet of Things and other technologies to break the traditional process; and Numerous new devices and products have been developed, which play an important role in drug development and production
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
For example, Merck announced recently that it has discontinued the Phase 3 clinical trial of its PD-1 product Keridax and the PARP inhibitor lipdrox in the treatment of metastatic castration-resistant prostate cancer because, after an interim data analysis, it was found that , compared with the control group abiraterone acetate or enzalutamide, Kreida combined with lipdroid did not show a survival benefit
.
Pharmaceutical companies have embarked on the road of innovation (Source: Pharmaceutical Network) In addition, on March 14, Sanofi also announced amcenestrant as a second-line or multi-line monotherapy for the treatment of ER+/HER2- advanced or metastatic breast cancer.
There was no news that the trial met its primary endpoint
.
According to an independent central review assessment, amcenestrant did not improve progression-free survival compared with a physician's choice of single-agent endocrine therapy
.
In addition to the above companies, many pharmaceutical companies have encountered setbacks in drug research and development this year, including Beijing Kangchen's withdrawal of the clinical trial application for teriparatide injection, and the failure of Kodiak's ultra-long-acting anti-VEGF therapy Phase IIb/III clinical trials.
.
.
According to the industry, the investment of large pharmaceutical companies in drug innovation has been increasing in recent years, but there are still very few new drugs that can enter the market every year, and the number of failed new drug R&D projects is still increasing day by day
.
Innovative drugs represent a country's technical level and capabilities in the field of medicine, and judging from the repeated "premature deaths" of innovative drug research and development, pharmaceutical companies still have a long way to go in new drug research and development
.
It is understood that the research and development of new drugs has always been difficult and the technical threshold is high.
The success rate from compound screening to listing is only 3‰.
The research and development of each innovative drug takes at least 10 years, and the initial investment cost is high
.
Taking the United States, which has a high level of innovative drug research and development as an example, the average cumulative investment of a single innovative drug is 600 million to 1 billion US dollars, while the average innovative drug research and development in China is as high as several hundred million yuan.
.
In this context, for domestic and foreign pharmaceutical companies, it is still not easy to develop a new drug
.
In the future, how to establish a project to develop new drugs with real clinical and market value, stand out from the homogeneous R&D, and accelerate the listing in China and even overseas will still be a long-term challenge faced by domestic pharmaceutical companies and new drug development institutions and will take time to research.
subject
.
In addition, it should be noted that under the background that innovation and research and development have become the general trend of pharmaceutical companies, as instruments and machines that directly contact drugs, the upgrading of pharmaceutical equipment cannot be ignored.
Whether it is quality upgrade or innovation upgrade, high-quality, High-tech and intelligent pharmaceutical equipment and instruments will bring more benefits to pharmaceutical companies
.
Especially in the current situation of accelerating innovation and reform of the domestic and foreign pharmaceutical industries, pharmaceutical equipment companies need to accelerate innovation and upgrading in order to help the pharmaceutical industry and pharmaceutical companies to further develop with high quality
.
It is reported that in fact, there are many pharmaceutical equipment companies, which are developing in the direction of multi-function, low energy consumption, intelligence and more suitable for pharmaceutical industrial production under the background of making full use of Internet, Internet of Things and other technologies to break the traditional process; and Numerous new devices and products have been developed, which play an important role in drug development and production
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
